Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson's disease: a cohort study

[1]  D. Berg,et al.  Neurodegenerative CSF markers in genetic and sporadic PD: Classification and prediction in a longitudinal study. , 2015, Parkinsonism & related disorders.

[2]  J. Trojanowski,et al.  Longitudinal study of normal cognition in Parkinson disease , 2015, Neurology.

[3]  D. Aarsland,et al.  Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease , 2015, Movement disorders : official journal of the Movement Disorder Society.

[4]  A. D'abreu,et al.  Clinical predictors of cognitive impairment and psychiatric complications in Parkinson's disease. , 2015, Arquivos de neuro-psiquiatria.

[5]  K. Cain,et al.  CSF tau and tau/Aβ42 predict cognitive decline in Parkinson's disease. , 2015, Parkinsonism & related disorders.

[6]  E. Tolosa,et al.  Dementia and severity of parkinsonism determines the handicap of patients in late‐stage Parkinson's disease: the Barcelona−Lisbon cohort , 2015, European journal of neurology.

[7]  Henrik Zetterberg,et al.  CSF biomarkers and clinical progression of Parkinson disease , 2015, Neurology.

[8]  J. Marinus,et al.  Predictors of dementia in Parkinson's disease; findings from a 5-year prospective study using the SCOPA-COG. , 2014, Parkinsonism & related disorders.

[9]  J. Ringman,et al.  Clinical predictors of severe cerebral amyloid angiopathy and influence of APOE genotype in persons with pathologically verified Alzheimer disease. , 2014, JAMA neurology.

[10]  K. Cain,et al.  Cerebrospinal fluid α-synuclein predicts cognitive decline in Parkinson disease progression in the DATATOP cohort. , 2014, The American journal of pathology.

[11]  Klaus P. Ebmeier,et al.  Predictors of cognitive impairment in an early stage Parkinson’s disease cohort , 2014, Movement disorders : official journal of the Movement Disorder Society.

[12]  Arthur W Toga,et al.  Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. , 2013, JAMA neurology.

[13]  P. Kempster,et al.  The Significance of α-Synuclein, Amyloid-β and Tau Pathologies in Parkinson's Disease Progression and Related Dementia , 2013, Neurodegenerative Diseases.

[14]  N. Bargalló,et al.  Combined dementia-risk biomarkers in Parkinson's disease: a prospective longitudinal study. , 2013, Parkinsonism & related disorders.

[15]  T. Robbins,et al.  The CamPaIGN study of Parkinson's disease: 10-year outlook in an incident population-based cohort , 2013, Journal of Neurology, Neurosurgery & Psychiatry.

[16]  Keith A. Johnson,et al.  Amyloid is linked to cognitive decline in patients with Parkinson disease without dementia , 2013, Neurology.

[17]  Gianmario Sambuceti,et al.  What predicts cognitive decline in de novo Parkinson's disease? , 2012, Neurobiology of Aging.

[18]  A. Singleton,et al.  The Parkinson Progression Marker Initiative (PPMI) , 2011, Progress in Neurobiology.

[19]  J. Trojanowski,et al.  CSF amyloid β 1-42 predicts cognitive decline in Parkinson disease , 2010, Neurology.

[20]  Jeffrey Kaye,et al.  Neuroimaging and Cognition in Parkinson's Disease Dementia , 2010, Brain pathology.

[21]  M. Weiner,et al.  Cerebrospinal fluid and plasma biomarkers in Alzheimer disease , 2010, Nature Reviews Neurology.

[22]  D. Aarsland,et al.  The epidemiology of dementia associated with Parkinson disease , 2010, Journal of the Neurological Sciences.

[23]  Zoran Bursac,et al.  Purposeful selection of variables in logistic regression , 2008, Source Code for Biology and Medicine.

[24]  Richard L. Doty,et al.  Combining Early Markers Strongly Predicts Conversion from Mild Cognitive Impairment to Alzheimer's Disease , 2008, Biological Psychiatry.

[25]  D. Eckstein,et al.  Parkinson's disease and dopaminergic therapy—differential effects on movement, reward and cognition , 2008, Brain : a journal of neurology.

[26]  Geert Mayer,et al.  The REM sleep behavior disorder screening questionnaire—A new diagnostic instrument , 2007, Movement disorders : official journal of the Movement Disorder Society.

[27]  K. Hugdahl,et al.  Subtypes of mild cognitive impairment in parkinson's disease: Progression to dementia , 2006, Movement disorders : official journal of the Movement Disorder Society.

[28]  I. McKeith,et al.  Motor subtype and cognitive decline in Parkinson’s disease, Parkinson’s disease with dementia, and dementia with Lewy bodies , 2006, Journal of Neurology, Neurosurgery & Psychiatry.

[29]  R. Gur,et al.  Striatal dopamine transporters and cognitive functioning in healthy men and women. , 2001, The American journal of psychiatry.

[30]  R Z Omar,et al.  Outlet strut fracture of Björk-Shiley convexo concave heart valves: the UK cohort study , 2001, Heart.

[31]  D. Altman,et al.  Comparing methods of measurement: why plotting difference against standard method is misleading , 1995, The Lancet.

[32]  J. Jankovic,et al.  Variable expression of Parkinson's disease , 1990, Neurology.

[33]  R. Doty,et al.  Development of the university of pennsylvania smell identification test: A standardized microencapsulated test of olfactory function , 1984, Physiology & Behavior.

[34]  K. Marder,et al.  CSF β-Amyloid 1-42 Predicts Progression to Cognitive Impairment in Newly Diagnosed Parkinson Disease , 2015, Journal of Molecular Neuroscience.

[35]  Hollis G. Potter,et al.  Author Manuscript , 2013 .

[36]  P. Hobson,et al.  Use of the GDS-15 geriatric depression scale as a screening instrument for depressive symptomatology in patients with Parkinson's disease and their carers in the community. , 1999, Age and ageing.